Does Renal Mass Ablation Provide Adequate Long-term Oncologic Control?
| Autor: | Stephen Faddegon, Jeffrey A. Cadeddu |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Percutaneous Radiofrequency ablation Urology medicine.medical_treatment Context (language use) Cryosurgery Nephrectomy Risk Assessment law.invention law Biopsy medicine Renal mass Humans Minimally Invasive Surgical Procedures Neoplasm Invasiveness Survival rate Neoplasm Staging medicine.diagnostic_test business.industry Biopsy Needle Cryoablation Ablation Immunohistochemistry Kidney Neoplasms Surgery Survival Rate Treatment Outcome Catheter Ablation Female Radiology Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Urologic Clinics of North America. 39:181-190 |
| ISSN: | 0094-0143 |
| DOI: | 10.1016/j.ucl.2012.01.004 |
| Popis: | Renal ablation (RA) is no longer used exclusively in patients with limited life expectancy. There are few studies reporting a minimum follow-up of 5 years. Biases and discrepancies within the literature are abundant. The outcomes of any series must be interpreted in the context of median follow-up time, reported tumor characteristics, ablation technique and training background of the practitioner, and the definition of tumor recurrence. The long-term oncologic efficacy of radiofrequency ablation (RFA) and cryoablation appear similar, although the percutaneous RFA technique may necessitate reablation in more cases. RA is associated with slightly higher rates of local recurrence compared to surgical excision. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|